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Implications for Nursing Care
Because BV increases risk for acquiring STIs, including HIV, the CDC 
recommends concurrent testing for Chlamydia, Gonorrhea, 
Trichomonas and HIV when screening patients for bacterial vaginosis 
(Bagnall & Rizzolo, 2017).  Women being treated for BV should also be 
counseled on safe sex practices.
Further research must be done that leads to the development of more 
effective therapies and proper treatment guidelines for recurrent BV.  
The APN should keep abreast of emerging research and new therapies 
in order to provide the most exceptional patient care.
Yeast infections are a common consequence of BV treatment, and can 
be easily treated with 150 mg oral Fluconazole (Bagnall & Rizzolo, 
2017). 
The APN should be mindful of the psychological impact this disease can 
have on patients.  Women may feel shame due to the discharge and 
malodor, and avoid sexual activity (Bagnall & Rizzolo, 2017).
Patient education is a very important component of treatment and 
prevention in bacterial vaginosis.
Patients prescribed oral metronidazole must be informed to avoid 
alcohol while taking the medication to prevent a disulfiram-like 
reaction (Bagnall & Rizzolo, 2017).
Patients should be provided with information on risk factors for BV and 
counseled on behavioral prevention interventions.
Patients should be advised to take probiotics or eat yogurt with 
lactobacilli to recolonize normal flora (ACNM, 2015).
Conclusions
Bacterial vaginosis affects 29% of women (Bagnall & Rizzolo, 2017).  It is 
vital that clinicians are knowledgeable about this disorder as they are 
highly likely to encounter it in practice due to its high prevalence.  
Clinicians must also stay informed of the latest 
research and new therapies to best help their 
patients as current therapies do not eradicate 
the disease for almost half of affected women.
Having BV increases the risk of acquiring and 
transmitting HIV (Machado & Cerca, 2015).  
Thus, treatment and prevention of bacterial 




• Thin, white or gray vaginal 
discharge
• Fishy odor, especially after 
sex
• Vaginal burning or itching
• Dyspareunia (pain during 
sexual intercourse)
• Dysuria (pain when urinating)
• Many women are 
asymptomatic
(American College of Nurse
Midwives [ACNM], 2015)
Diagnosis
Diagnosis of BV is based on Amsel
criteria.  Three of the four criteria 
must be met for a positive 
diagnosis:
• pH > 4.5 (measured with pH 
strips)
• Thin, white or gray discharge
• Fishy odor after addition of 
10% potassium hydroxide to 
vaginal smear (Whiff test)
• At least 20% clue cells on wet 
mount microscopy  
(Bagnall & Rizzolo, 2017)
Treatment
The following treatment options 
are recommended by the CDC for 
bacterial vaginosis:
• Metronidazole 500 mg, orally 
twice a day for 7 days
• 0.75% metronidazole gel, one 
applicator intravaginally 
every night for 5 nights
• 2% clindamycin cream, one 
applicator intravaginally 
every night for 7 nights
(Bagnall & Rizzolo, 2017)
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Normal vaginal flora is predominated by lactobacilli that produce hydrogen-peroxide and lactic acid, 
creating an acidic environment that is inhospitable to invading bacteria (Machado & Cerca, 2015).
Lactobacilli also secrete antimicrobial substances that have bactericidal activity or prevent the 
adhesion of other microbes to the vaginal epithelial surface (Parma, Stella Vanni, Bertini, & Candiani, 
2014).
In BV, the normal flora is replaced by Gardnerella vaginalis which leads to an alkaline environment 
(Bagnall & Rizzolo, 2017).
G. vaginalis possesses 3 virulence factors that contribute to its pathogenicity in BV:  ability to adhere 
to vaginal epithelial cells, biofilm production, and cytotoxicity (Machado & Cerca, 2015).
G. vaginalis produces a biofilm on the epithelial surface which serves as a platform for other 
pathogenic bacteria to adhere to. This biofilm also protects the pathogens by hindering antibiotic 
penetration (Bagnall & Rizzolo, 2017).
Diagnostic criteria for BV includes the presence of clue cells in vaginal secretions.  Clue cells are 
desquamated biofilm-coated epithelial cells (Machado & Cerca, 2015).
Introduction
Bacterial vaginosis (BV) is 
described as a dysbiosis, or a 
microbial imbalance in the 
normal vaginal flora.  Anaerobic 
pathogenic bacteria outgrow the 
normal, protective lactobacilli 
leading to symptoms of 
abnormal vaginal discharge and 
malodor (Muzny & Schwebke, 
2016).
BV affects 21 million women in 
the United States alone (Bagnall 
& Rizzolo, 2017).  It is the most 
common vaginal disorder in 
women ages 15 to 44 years 
(Centers for Disease Control and 
Prevention [CDC], 2017).
Serious complications from BV 
include preterm labor, pelvic 
inflammatory disease, 
postoperative infections and 
increased risk for acquiring 
sexually transmitted infections 
(STIs), including HIV (Bagnall & 
Rizzolo, 2017; Machado & Cerca, 
2015).
50% of women treated for BV 
have recurring symptoms within 
12 months (Bagnall & Rizzolo, 
2017).
Risk factors for BV include:
- Black or Hispanic ethnicity
- Douching
- Use of vaginal deodorants
- Smoking
- New or multiple sex
partners (SPs)
- Lack of condom use
- Women who have sex with
women
(Bagnall & Rizzolo, 2017).
Importance of Topic
The advanced practice nurse 
(APN) should have significant 
understanding of this disorder 
since it is so prevalent and 
recurring among the female 
population.  It has been noted by 
a public health nurse employed at 
a sexual health clinic that many 
female patients diagnosed with 
BV, either for the first time or 
recurrently, are unaware of the 
risk factors and methods of 
prevention.  It is important for 
future clinicians to be 
knowledgeable on the risk 
factors, diagnostic criteria and 
most current treatment so that 
patients with BV are 
appropriately treated and 
educated to prevent recurrences 
or serious complications. 
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Significance of Pathophysiology
There are several hypotheses on the pathogenesis of bacterial 
vaginosis, however, the exact cause or mechanism that leads to 
the microbial shift characteristic of BV is unknown (Muzny & 
Schwebke, 2016).
Continued research is imperative for the development of more 
efficacious treatments and improved patient education and 
prevention.
Knowledge of the pathogenicity of G. vaginalis can be used to 
create new medications targeting this microbe which appears to 
be the primary invader in BV.
Research suggests that BV is an STI (Bagnall & Rizzolo, 2017; 
Muzney & Schwebke, 2016).  However, the Centers for Disease 
Control and Prevention (CDC) does not classify BV as an STI, nor 
does it recommend treatment for male partners of BV-positive 
females (CDC, 2017).
Conclusive evidence is needed to determine the role of sexual 
activity in the pathogenesis of BV.  Proper classification of BV is 
necessary for better prevention and control of the disease.
